• A preservative-free, single-dose formulation of a bimatoprost-timolol ophthalmic solution made by Allergan, Inc., has received marketing approval in the 27 European Union countries.

    A combination of bimatoprost 0.03% and timolol 0.5%, Ganfort is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension that is insufficiently responsive to topical beta-blockers or prostaglandin analogs.

    The new unit dose formulation, expected to be available by mid-September, was shown in a 12-week study to be noninferior to the multidose formula while maintaining equivalent efficacy, the release said. Because it is in a single dose, preservatives are not needed, refrigeration is not required and patients can use it in the morning or evening.